What AIM IMMUNOTECH INC. does

AIM ImmunoTech Inc. is a publicly traded (NYSE American: AIM) clinical-stage immuno-pharmaceutical company headquartered in Ocala, Florida. Its sole core product is Ampligen® (rintatolimod), a double-stranded RNA immuno-modulator that is the only known TLR agonist to exclusively activate the TRIF adaptor pathway while avoiding the MyD88 inflammatory cascade and helicase-driven NF-κB activation. Approximately 100,000 IV doses have been administered across clinical and named-patient settings, providing a sizable safety/experience dataset. Ampligen is approved in Argentina for severe chronic fatigue syndrome and is being evaluated in late-stage pancreatic cancer (Phase 2 DURIPANC with AstraZeneca's Imfinzi at Erasmus Medical Center), recurrent ovarian cancer (Phase 2 with pembrolizumab and cisplatin at UPMC, supported by Merck), triple-negative breast cancer, colorectal cancer, ME/CFS, post-COVID conditions, and Ebola preparedness.

The company is pre-revenue from a commercial standpoint, generating approximately $110,000 in trailing twelve month revenue, and operates with 11–50 employees. Its go-to-market is anchored on FDA and EMA regulatory approval pathways, supplemented by a Dutch government-approved Named Patient Program at Erasmus Medical Center that has treated 82+ pancreatic cancer patients with Ampligen monotherapy. Distribution upon approval is expected to flow through standard hospital and specialty oncology pharmacy channels. AIM is positioning Ampligen for either licensing/out-licensing or acquisition by larger pharmaceutical companies following regulatory clarity.

AIM finances its pipeline through repeated registered direct offerings, warrant inducements, and rights offerings — completing eight financings between February 2024 and June 2026 totaling roughly $22–25 million, with Maxim Group LLC and Ladenburg Thalmann as recurring placement agents. The company executed a 1-for-100 reverse stock split in June 2025 to regain NYSE American compliance, and its market capitalization stood at approximately $2.51 million as of May 2026, reflecting a high-risk, capital-constrained profile typical of late-stage development biotechs.

Name

AIM IMMUNOTECH INC.

Legal name

AIM ImmunoTech Inc.

Website

https://aimimmuno.com

Company type

Public

Founded year

1990

Operating status

Operating

Headcount range

11–50 employees

Short description

AIM ImmunoTech is a pre-revenue, publicly traded clinical-stage immuno-pharma company developing Ampligen (rintatolimod), a TLR3/TRIF-pathway immuno-modulator, for late-stage pancreatic cancer, recurrent ovarian cancer, and viral/immune disorders, with FDA and EMA orphan drug designations.

Ownership category

akta.pro rank

Product category

Immuno-Oncology Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)

akta.pro secondary industries

Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Immuno-pharmaceutical therapeutics
• Oncology drug development
• Antiviral drug development
• Immune disorder therapeutics
• Clinical stage biopharmaceutical

Headquarters

HQ city

Ocala

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Product Revenue (Future): The company is pre-revenue and focused on developing Ampligen for regulatory approval. Once approved, the company expects to generate revenue through product sales for the treatment of late-stage pancreatic cancer and other indications.
2. Licensing and Partnerships: AIM is positioning Ampligen for potential licensing or acquisition by larger pharmaceutical companies once regulatory pathways are clarified. The company has received attention from major biotech M&A deals involving oncology drugs in later-stage development.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

AIM ImmunoTech is developing Ampligen (rintatolimod), a synthetic dsRNA immuno-modulator that selectively activates the TLR3/TRIF pathway, as a therapeutic candidate for late-stage pancreatic cancer (Phase 2 DURIPANC in combination with AstraZeneca's Imfinzi), recurrent ovarian cancer, triple-negative breast cancer, colorectal cancer, ME/CFS, and viral diseases such as COVID-19/Long COVID and Ebola. The product is approved in Argentina for severe chronic fatigue syndrome and is pre-revenue in the US/EU pending regulatory approval, with Phase 3 pancreatic cancer trial design underway with Thermo Fisher's PPD.

Product overview

AIM ImmunoTech is an immuno-pharma company with a single core product—Ampligen® (rintatolimod), a dsRNA immuno-modulator. Ampligen is being developed across multiple therapeutic areas: oncology (pancreatic cancer, ovarian cancer, triple-negative breast cancer, colorectal cancer), immune disorders (ME/CFS), and viral diseases (COVID-19, Ebola). The product is approved in Argentina for severe CFS and is advancing through Phase 2 clinical trials, particularly the DURIPANC study evaluating Ampligen in combination with AstraZeneca's Imfinzi for metastatic pancreatic cancer.

Differentiator

Problem solved

Functional benefit

Products and services

• Ampligen (rintatolimod) Ampligen is a synthetic double-stranded RNA (dsRNA) immuno-modulator being developed by AIM ImmunoTech for a range of cancers, viral diseases, and immune disorders. It is currently approved in Argentina for severe chronic fatigue syndrome (CFS) and is undergoing clinical evaluation in the US and EU for metastatic and locally advanced pancreatic cancer (Phase 2 DURIPANC study in combination with AstraZeneca's Imfinzi), recurrent ovarian cancer (in combination with Merck's pembrolizumab and cisplatin at UPMC), triple-negative breast cancer, colorectal cancer, ME/CFS, post-COVID conditions, and Ebola virus disease preparedness.

Quantifiable outcome

• Median overall survival of 19.7 months vs 8.6 months standard of care in pancreatic cancer patients
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core.

• Thermo Fisher Scientific (PPD Clinical Research)coreImplementation/ SI/ Consulting Partner · 1 March 2026AIM entered into an agreement with Thermo Fisher Scientific's PPD clinical research business to design the planned Phase 3 clinical trial for Ampligen in late-stage pancreatic cancer treatment.
• Merck Sharp & DohmecoreStrategic or Co-development Partner · 1 May 2025Merck Sharp & Dohme collaborated on the Phase 2 clinical trial evaluating Ampligen in combination with pembrolizumab and cisplatin for recurrent ovarian cancer, providing financial support through a grant and collaborating on the UPMC study.
• AstraZenecacoreStrategic or Co-development Partner · 18 June 2024AstraZeneca is collaborating with AIM ImmunoTech on the Phase 2 DURIPANC clinical trial evaluating Ampligen in combination with AstraZeneca's Imfinzi (durvalumab) for metastatic pancreatic cancer. This is a joint collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands, designed to generate biomarker data to support a pivotal Phase 3 clinical trial.
• Erasmus Medical CentercoreStrategic or Co-development PartnerErasmus Medical Center in the Netherlands is collaborating on the Phase 2 DURIPANC clinical trial and operates the Dutch government-approved Named Patient Program treating pancreatic cancer patients with Ampligen.
• University of Pittsburgh Medical Center (UPMC)coreStrategic or Co-development PartnerUPMC collaborated on Phase 2 clinical trials evaluating Ampligen in combination with pembrolizumab and cisplatin for recurrent ovarian cancer, achieving 50% objective response rate with 21% complete responses.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Idera Pharmaceuticals (now Aceragen): Developed TLR3 and TLR9 agonists for oncology and rare diseases, making it a direct mechanistic peer to AIM ImmunoTech. Both companies operated in the TLR agonist space with similar strategic rationales around immuno-modulation, though Aceragen has since refocused on rare disease therapeutics.
• Hemispherx Biopharma: Historically the developer of Ampligen (rintatolimod) and predecessor entity to AIM ImmunoTech. Focused on the same Ampligen asset for ME/CFS and oncology, providing the most direct historical comparator for AIM's clinical and commercial trajectory.
• Rafael Pharmaceuticals: Developed CPI-006 (a TLR agonist) and other oncology therapeutics, with significant focus on pancreatic cancer. Comparable to AIM as a clinical-stage immuno-oncology company targeting the same difficult-to-treat pancreatic cancer indication.
• Cardiff Oncology: Clinical-stage oncology company developing therapeutics for pancreatic cancer and other solid tumors, with a focus on combinations. Directly comparable as a small-cap, pre-revenue immuno-oncology peer in the same pancreatic cancer indication.
• Panbela Therapeutics: Late-stage clinical biotech developing therapeutics for pancreatic cancer. Comparable as a small-cap, pancreatic cancer-focused peer with similar regulatory milestones and capital markets profile.
• Cantex Pharmaceuticals: Clinical-stage pharmaceutical company developing therapeutics for pancreatic cancer and other oncology indications. Comparable as a small-cap peer focused on difficult-to-treat pancreatic cancer.

Emerging players

• Heat Biologics: Clinical-stage immuno-oncology company developing T-cell activating platforms for solid tumors. Comparable as a small-cap peer in the immuno-oncology space with similar TLR-adjacent mechanism and clinical-stage profile.
• Agenus: Clinical-stage immuno-oncology company developing checkpoint inhibitor combinations and immune-modulating therapies. Directly comparable in pursuing combination immunotherapy strategies with major pharma partners.
• Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing immune-stimulating antibody conjugates for solid tumors. Comparable as a small-cap clinical-stage peer using novel immune-modulation mechanisms in oncology combinations.

Broad incumbents

• Moderna: Large commercial-stage mRNA therapeutics company with TLR-mediated immune activation as part of its platform. While much larger and broader, Moderna represents an incumbent in the nucleic acid-based immuno-modulator space that competes for similar clinical and capital resources.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/AIMImmuno
• Facebookfacebook.com/AIM-ImmunoTech-Inc-109318447106712
• LinkedInlinkedin.com/company/aimimmuno

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds7 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AIM IMMUNOTECH INC.